Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction.

Finding specific small-molecule inhibitors of protein-protein interactions remains a significant challenge. Recently, attention has grown toward "hot spot" interactions where binding is dominated by a limited number of amino acid contacts, theoretically offering an increased opportunity for disruption by small molecules. Inhibitors of the interaction between BRCT (the C-terminal portion of BRCA1, a key tumor suppressor protein with various functions) and phosphorylated proteins (Abraxas/BACH1/CtIP), implicated in DNA damage response and repair pathways, should prove to be useful in studying BRCA1's role in cancer and in potentially sensitizing tumors to chemotherapeutic agents. We developed and miniaturized to a 1536-well format and 3-mul final volume a pair of fluorescence polarization (FP) assays using fluorescein- and rhodamine-labeled pBACH1 fragment. To minimize the effect of fluorescence artifacts and to increase the overall robustness of the screen, the 75,552 compound library members all were assayed against both the fluorescein- and rhodamine-labeled probe-protein complexes in separate but interleaved reactions. In addition, every library compound was tested over a range of concentrations following the quantitative high-throughput screening (qHTS) paradigm. Analyses of the screening results led to the selection and subsequent confirmation of 16 compounds active in both assays. Faced with a traditionally difficult protein-protein interaction assay, by performing two-fluorophore qHTS, we were able to confidently select a number of actives for further studies.

[1]  Michelle R. Arkin,et al.  Binding of small molecules to an adaptive protein–protein interface , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Anton Simeonov,et al.  Quantitative High-Throughput Screen Identifies Inhibitors of the Schistosoma mansoni Redox Cascade , 2008, PLoS neglected tropical diseases.

[3]  Junjie Chen,et al.  CCDC98 is a BRCA1-BRCT domain–binding protein involved in the DNA damage response , 2007, Nature Structural &Molecular Biology.

[4]  P. Cleveland,et al.  Nanoliter dispensing for uHTS using pin tools. , 2005, Assay and drug development technologies.

[5]  Hua Tang,et al.  Studies on Repository Compound Stability in DMSO under Various Conditions , 2003, Journal of biomolecular screening.

[6]  Sam Michael,et al.  Compound Management for Quantitative High-Throughput Screening , 2008, JALA.

[7]  Junjie Chen,et al.  DNA Damage-Induced Cell Cycle Checkpoint Control Requires CtIP, a Phosphorylation-Dependent Binding Partner of BRCA1 C-Terminal Domains , 2004, Molecular and Cellular Biology.

[8]  J. Tesmer Pharmacology. Hitting the hot spots of cell signaling cascades. , 2006, Science.

[9]  Xiaochun Yu,et al.  CCDC98 targets BRCA1 to DNA damage sites , 2007, Nature Structural &Molecular Biology.

[10]  David Eisenberg,et al.  A Novel Inhibitor of Mycobacterium tuberculosis Pantothenate Synthetase , 2007, Journal of biomolecular screening.

[11]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[12]  Junjie Chen,et al.  Ubiquitin-Binding Protein RAP80 Mediates BRCA1-Dependent DNA Damage Response , 2007, Science.

[13]  Yigong Shi,et al.  Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. , 2004, Molecular cell.

[14]  Drew M. Lowery,et al.  Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer , 2004, Nature Structural &Molecular Biology.

[15]  B. K. Muralidhara,et al.  Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design. , 2007, Journal of the American Chemical Society.

[16]  T Pérez-Ruiz,et al.  Simultaneous determination of doxorubicin, daunorubicin, and idarubicin by capillary electrophoresis with laser‐induced fluorescence detection , 2001, Electrophoresis.

[17]  D. Sgroi,et al.  BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function , 2001, Cell.

[18]  A. Bogan,et al.  Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.

[19]  S. Macura,et al.  Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. , 2004, Structure.

[20]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[21]  A. Varma,et al.  Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex. , 2005, Biochemistry.

[22]  Michael B Yaffe,et al.  BRCT Repeats As Phosphopeptide-Binding Modules Involved in Protein Targeting , 2003, Science.

[23]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Kim E. Garbison,et al.  The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies , 2006, Journal of biomolecular screening.

[25]  J. Glover,et al.  Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1 , 2004, Nature Structural &Molecular Biology.

[26]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .

[27]  Steven P Gygi,et al.  Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response , 2007, Science.

[28]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[29]  Georges Mer,et al.  The BRCT Domain Is a Phospho-Protein Binding Domain , 2003, Science.

[30]  Aedín C Culhane,et al.  RAP80 Targets BRCA1 to Specific Ubiquitin Structures at DNA Damage Sites , 2007, Science.

[31]  Sandra L. Nelson,et al.  The Effect of Room-Temperature Storage on the Stability of Compounds in DMSO , 2003, Journal of biomolecular screening.

[32]  Peter J. Coassin,et al.  Piezo- and solenoid valve-based liquid dispensing for miniaturized assays. , 2005, Assay and drug development technologies.

[33]  Christopher P Austin,et al.  High-throughput screening assays for the identification of chemical probes. , 2007, Nature chemical biology.

[34]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[35]  A. Natarajan,et al.  High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1. , 2006, Analytical biochemistry.

[36]  A. Bowcock,et al.  The C-terminal (BRCT) Domains of BRCA1 Interact in Vivo with CtIP, a Protein Implicated in the CtBP Pathway of Transcriptional Repression* , 1998, The Journal of Biological Chemistry.

[37]  Junjie Chen,et al.  Phosphopeptide Binding Specificities of BRCA1 COOH-terminal (BRCT) Domains* , 2003, Journal of Biological Chemistry.

[38]  T. Insel,et al.  NIH Molecular Libraries Initiative , 2004, Science.